Validation, implementation, and clinical impact of the Oncomine Myeloid targeted-amplicon DNA and RNA ion semiconductor sequencing assay

We present validation of the Thermo Fisher Oncomine Myeloid NGS Panel (OMP), targeting 40 genes and 29 fusion drivers recurrently mutated in myeloid malignancies. The study includes data from a sample exchange between two Canadian hospitals demonstrating high concordance for detection of DNA and RNA aberrations.

https://www.jmdjournal.org/article/S1525-1578(21)00234-8/fulltext?rss=yes

Source: Journal of Molecular Diagnostics - August 5, 2021 Category: Pathology Authors: Christina K. Ferrone, Henry Wong, Laura Semenuk, Barnaba Werunga, Brooke Snetsinger, Xiao Zhang, Grace Zhang, Janet Lui, Guillaume Richard-Carpentier, Susan Crocker, David Good, Annette E. Hay, Graeme Quest, Nancy Carson, Harriet E. Feilotter, Michael J. Tags: Regular Article Source Type: research